Trial reportThe American journal of drug and alcohol abuse2014
Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder.
Trial report in The American journal of drug and alcohol abuse, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00316277 (A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Standard Medical Management or Enhanced Medical Management for Opioid Analgesic Dependence), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Standard Medical Management or Enhanced Medical Management for Opioid Analgesic Dependence
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Health harms of non-medical prescription opioid use: A systematic review.Drug and alcohol review · 2022Pooled it
- Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.Addiction (Abingdon, England) · 2022Trial
- Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone.Drug and alcohol dependence · 2021Trial
- Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.Experimental and clinical psychopharmacology · 2018Trial
- The Prescription Opioid Addiction Treatment Study: What have we learned.Drug and alcohol dependence · 2017Trial
- The impact of addiction medications on treatment outcomes for persons with co-occurring PTSD and opioid use disorders.The American journal on addictions · 2015Trial
- Impact of Co-Occurring Psychiatric Comorbidities and Substance Use Disorders on Outcomes in Adolescents and Young Adults with Opioid Use Disorder: A Retrospective Cohort Study.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Exploring dual diagnosis in opioid agonist treatment patients: a registry-linkage study in Czechia and Norway.Addiction science & clinical practice · 2024Article
- Investigating social deprivation and comorbid mental health diagnosis as predictors of treatment access among patients with an opioid use disorder using substance use services: a prospective cohort study.Substance abuse treatment, prevention, and policy · 2023Article
- Association Between Receipt of Antidepressants and Retention in Buprenorphine Treatment for Opioid Use Disorder: A Population-Based Retrospective Cohort Study.The Journal of clinical psychiatry · 2022Article
- Changes in pain during buprenorphine maintenance treatment among patients with opioid use disorder and chronic pain.Journal of consulting and clinical psychology · 2022Article
- Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder.Advances in drug and alcohol research · 2022Article
- Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.Addiction science & clinical practice · 2021Article
- A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data.Harm reduction journal · 2020Article
- Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.Addiction (Abingdon, England) · 2020Article
- Diverse diagnostic profiles associated with prescription opioid use disorder in a nationwide sample: One crisis, multiple needs.Journal of consulting and clinical psychology · 2019Article
- Long-term retention in Office Based Opioid Treatment with buprenorphine.Journal of substance abuse treatment · 2017Article
- Dependence on Prescription Opioids.Deutsches Arzteblatt international · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundGiven the growing prevalence of prescription opioid dependence and the considerable rates of additional psychopathology in drug dependence, we examined the association between the presence of a co-occurring Axis I psychiatric disorder and sociodemographic and clinical characteristics in this secondary analysis of patients entering a treatment study for dependence on prescription opioids. Treatment outcomes were also compared.
methodsPatients dependent on prescription opioids participated in a multi-site, two-phase, randomized, controlled trial to assess different lengths of buprenorphine-naloxone pharmacotherapy and different intensities of counseling (Clinicaltrials.gov identifier: NCT00316277). Among the 653 participants entering the first phase of the trial, 360 entered the second phase, receiving 12 weeks of buprenorphine-naloxone treatment; they are reported here. Half of those participants (180/360) had a current co-occurring psychiatric disorder in addition to substance dependence.
resultsSociodemographic characteristics were similar overall between those with and without a co-occurring psychiatric disorder, but women were 1.6 times more likely than men to have a co-occurring disorder. On several clinical indicators at baseline, participants with a co-occurring disorder had greater impairment. However, they had better opioid use outcomes at the conclusion of 12 weeks of buprenorphine-naloxone stabilization than did participants without a co-occurring disorder.
conclusionsPrescription opioid-dependent patients with a co-occurring psychiatric disorder had a better response to buprenorphine-naloxone treatment despite demonstrating greater impairment at baseline. Additional research is needed to determine the mechanism of this finding and to adapt treatments to address this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.